A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 518-525

  Lin, Ching Hua ^a   Kuo, Chao Chan ^a   Chou, Li Shiu ^a   Chen, Yeng Hung ^a   Chen, Cheng Chung ^a   Huang, Kuo Hao ^b   Lane, Hsien Yuan ^b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Sunshine Psychiatric Hospital   (Taiwan)

Author keywords

antipsychotic drug combination; haloperidol; risperidone; schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; HALOPERIDOL; RISPERIDONE;

ADULT; AKATHISIA; AMENORRHEA; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXCESSIVE DREAMING; FATIGUE; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERSALIVATION; HYPOSALIVATION; LIBIDO DISORDER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MONOTHERAPY; MUSCLE RIGIDITY; ORGASM DISORDER; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STRESS; TREMOR; VAGINAL DRYNESS; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PROLACTIN; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957287124     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f28dff     Document Type: Article

References (48)

1. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10: 79-104. (Pubitemid 40139590)
2. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373: 31-41.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60: 553-564. (Pubitemid 36682312)
4. Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004;24: 582-591. (Pubitemid 39518652)
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353: 1209-1223. (Pubitemid 41345943)
6. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5: 26. (Pubitemid 41460700)
7. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull. 2002;28: 105-109.
8. Loosbrock DL, Zhao Z, Johnstone BM, et al. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ. 2003;6: 67-75. (Pubitemid 37304742)
9. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003;12: 41-48. (Pubitemid 36192948)
10. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65: 1377-1388.
11. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161: 700-706. (Pubitemid 38445515)
12. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002;28: 75-84.
13. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54: 55-59. (Pubitemid 36043847)
14. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother. 2003;37: 951-955.
15. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48: 739-745.
16. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156: 286-293. (Pubitemid 29077120)
17. Schatzberg A, Nemeroff C. Textbook of Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing, Inc; 2009: 627-640.
18. American Psychiatric Association. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1994.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: DHEW Publication; 1976: 76338.
20. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45: 789-796.
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276. (Pubitemid 18039085)
22. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994;11: 239-244. (Pubitemid 24063743)
23. Moos RH, Nichol AC, Moos BS. Global Assessment of Functioning ratings and the allocation and outcomes of mental health services. Psychiatr Serv. 2002;53: 730-737.
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154: 672-676.
25. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212: 11-19.
26. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;334(suppl): 1-100.
27. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305: 160-164.
28. Zhong KX, Sweitzer DE, Hamer RM, et al. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry. 2006;67: 1093-1103.
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
30. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156: 869-875. (Pubitemid 29260341)
31. Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995;57: 103-107.
32. Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry. 2006;67: 1813-1814. (Pubitemid 44955164)
33. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62: 1196-1204.
34. Tada M, Shirakawa K, Matsuoka N, et al. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology (Berl). 2004;176: 94-100. (Pubitemid 39506372)
35. Lane HY, Chiu WC, Chou JC, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry. 2000;61: 209-214.
36. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry. 2001;62: 282-289. (Pubitemid 32428768)
37. Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol. 2006;20: 86-90.
38. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64: 663-667.
39. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res. 1998;32: 215-228. (Pubitemid 28409549)
40. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry. 2002;159: 1932-1935. (Pubitemid 35283263)
41. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65: 57-61.
42. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302: 1129-1134. (Pubitemid 34920235)
43. Bressan RA, Erlandsson K, Spencer EP, et al. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl). 2004;175: 367-373. (Pubitemid 39361925)
44. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19: 57-61. (Pubitemid 29047332)
45. Forthofer RN, Lee ES, Hernandez M. Biostatistics: A Guide to Design, Analysis, and Discovery. 2nd ed. San Diego, CA: Elsevier Inc; 2007: 149-154.
46. Schatzberg A, Nemeroff C, eds. Textbook of psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing, Inc; 2009: 533-554.
47. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin psychiatry. 2009;70: 829-836.
48. Lykouras L, Oulis P, Psarros K, et al. Five-factor model of schizophrenic psychopathology: how valid is it? Eur Arch Psychiatry Clin Neurosci. 2000;250: 93-100. (Pubitemid 30326322)